Annals of Oncology
Издатель: Elsevier · ISSN 0923-7534 · 64 статей
- Predict. Support. Act? DeepComp and post-operative risk in gastric cancer
- Keeping the story, turning the page: from prognostic to predictive AI in high-risk prostate cancer
- The return of the adult thymus in radiation oncology?
- Updated treatment recommendations for systemic treatment: from the ESMO oncogene-addicted metastatic non-small cell lung cancer Living Guideline
- HER2-directed TAC T cells in solid tumors: a step forward, but not yet a therapeutic leap
- Next-generation sequencing consensus guidelines for sarcoma: progress, gaps, and the path forward
- Multimodal artificial intelligence prediction of abiraterone efficacy in two STAMPEDE phase III trials of nonmetastatic very high-risk prostate cancer☆
- Thymic radiation is associated with worse outcomes in patients with NSCLC
- Autologous T-cell antigen coupler targeting HER2 (TAC01-HER2) in advanced or metastatic solid tumors
- Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer☆
- A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial
- SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer☆
- Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial
- A multimodal deep learning model for preoperative prediction of post-operative complications in gastric cancer
- Prompt-directed ambient artificial intelligence for automated multidisciplinary tumor board documentation
- Reply to “Next-generation sequencing consensus guidelines for sarcoma: progress, gaps, and the path forward”
- The ethical obligation to use positive trial results
- Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer: the HELEN-Trio 011 randomized clinical trial
- Corrigendum to “Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER)”: [Annals of Oncology 37 (2026) 1220-1229]
- The ESMO Scale for Clinical Actionability of Molecular Targets, version 2 (ESCAT v2): an evidence-based framework for ranking alterations as actionability and resistance biomarkers in precision oncology
- Active surveillance versus standard surgery after neoadjuvant chemoradiotherapy for oesophageal cancer: long-term results of a cluster-randomised controlled trial (SANO)
- Perioperative pembrolizumab or placebo plus neoadjuvant cisplatin and gemcitabine in participants with muscle-invasive bladder cancer who are eligible for cisplatin: the double-blind, phase III KEYNOTE-866 study
- Capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer: updated survival analysis from CAPItello-281☆
- Nivolumab plus relatlimab with platinum-doublet chemotherapy versus nivolumab with platinum-doublet chemotherapy in stage IV or recurrent non-small cell lung cancer: clinical, translational, and patient-reported outcomes results from the phase II RELATIVITY-104 study
- Neoadjuvant nivolumab plus gemcitabine–cisplatin followed by postsurgical adjuvant nivolumab versus neoadjuvant gemcitabine–cisplatin in patients with muscle-invasive bladder cancer: final results from the phase III CA017-078 trial☆
- Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2– early breast cancer: Six-year follow-up of the NATALEE trial
- Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR-positive, HER2-negative advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy☆
- Pembrolizumab Plus Chemotherapy for HR+/HER2− PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study
- Atirmociclib and fulvestrant for patients with HR-positive/HER2-negative advanced or metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial☆
- Adjuvant chemotherapy with cisplatin and gemcitabine compared with standard of care after curative intent resection of cholangiocarcinoma and muscle-invasive gallbladder carcinoma (ACTICCA-1/AIO-HEP-0112 trial)☆